Aceto to launch generic for ALS treatment
Aceto Corporation, Port Washington, N.Y., announced June 11 that its generics subsidiary, Rising Pharmaceuticals Inc., Paramus, N.J., will launch the 50-mg strength of riluzole tablets.
Aceto Corporation, Port Washington, N.Y., announced June 11 that its generics subsidiary, Rising Pharmaceuticals Inc., Paramus, N.J., will launch the 50-mg strength of riluzole tablets.
Riluzole is used to treat amyotrophic lateral sclerosis (ALS) and in 2012 generated $64 million in sales, according to IMS Health. Aceto’s product is an FDA-approved version of Covis Pharma's (Switzerland) Rilutek. Rising Pharmaceuticals has launched nine generic products in 2013.
Related Content
